Navigation Links
PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services

BOSTON, April 30 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, has appointed Imogene Grimes, Ph.D., to Vice President of Data Sciences Strategic Services. Dr. Grimes, a leading biostatistician with more than 25 years of experience, is contributing to the continued expansion of PAREXEL's data science services, including data management, biostatistics, and applications of information technology to the clinical development process. Her responsibilities include advising clients on clinical study design, analysis methodology, and related regulatory guidelines. Dr. Grimes provides support for strategic data services, such as preparation of integrated data files suitable for registration packages and preparation of electronic submissions, compliant with regulatory expectations.

"The biopharmaceutical industry is undertaking more complex clinical research such as using adaptive designs with the potential to detect safety and efficacy signals earlier. Dr. Grimes will bring experience with advanced statistical methods to PAREXEL, which we believe will be a tremendous asset to our clients in bringing novel treatments to patients sooner," said Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics at PAREXEL International.

"PAREXEL has one of the industry's largest and most deeply expert data sciences departments," said Barbara Tardiff, M.D., M.S., M. Phil., Corporate Vice President of Data Sciences, Clinical Research Services, PAREXEL. "We look forward to the contributions Dr. Grimes will make to further strengthen and expand our strategic data and informatics capabilities for clients globally as well as supporting our e-submissions strategies."

Prior to joining PAREXEL, Dr. Grimes served as Vice President, Statistics, Data Management and Informatics at Regeneron Pharmaceuticals, where she provided statistical and data management expertise for all phases of drug development research. Previously, she was Vice President Statistics and Data Management at Yamanouchi Pharma America, now Astellas Pharma, and held senior management positions at Pfizer and GlaxoSmithKline.

Dr. Grimes holds a Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill, and Master's and Bachelor's degrees from the University of North Carolina at Greensboro. A focus of Dr. Grimes' career has been regulatory submissions of marketing applications using electronic media and in particular ensuring an understanding of regulatory expectations for statistics and data management. She currently serves as a Board Member of the Data Quality Research Institute, and is a member of several industry organizations including the American Statistical Association and The International Biometric Society. Dr. Grimes has presented several training courses and has authored numerous articles on data management and statistics topics.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 63 locations throughout 52 countries around the world, and has more than 7,600 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL and IMPACT are registered trademarks of PAREXEL International Corporation, and PERCEPTIVE INFORMATICS is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.


Jennifer Baird, Rebecca Passo

Senior Director of Public Relations SHIFT Communications

PAREXEL International Tel: +617-779-1817

Tel: +781-434-4409 Email :


SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier global ... it has been selected by The Michael J. Fox ... lines to academic, pharmaceutical, and biotechnology organizations committed to ... the United States , and more than ... the United States , and more than ...
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... 8, 2015  Today, DuPont and Caribou Biosciences, ... editing, jointly announced a strategic alliance. As part ... respective patent portfolios, with DuPont receiving exclusive intellectual ... row crops, and non-exclusive rights in other agricultural ... --> --> In addition, the ...
(Date:10/8/2015)... Oct. 8, 2015  Today the Wyss Institute for ... of its start-up company Opsonix Inc. The ... Harvard,s Office of Technology Development (OTD) and Opsonix ... therapy for clinical use. --> ... a million people every year in the U.S. — ...
Breaking Biology Technology:
... Amnis Corporation announced today a,major new release ... 3.0 incorporates greatly expanded analytical capabilities,while maintaining an ... provides the user with dozens of new image ... analysis. The new software also provides the user ...
... 10 Cryo-Cell,International, Inc. (OTC Bulletin Board: CCEL) ... established family cord blood banks, today,announced results for ... Consolidated revenues for the first quarter were approximately ... $4.2,million for the first quarter of 2007. The ...
... April 10 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ... studies,of PX-478, pharmacodynamic studies of PX-12 and preclinical ... Meeting of the American Association,for Cancer Research (AACR) ... is currently conducting a Phase 1 clinical trial ...
Cached Biology Technology:
(Date:9/28/2015)...  The monitoring of vital signs, such as ... an essential component of patient assessment. Changes in ... a patient,s condition. However, in general care areas ... during routine observation rounds only once every four ... these observation rounds, the warning signs can go ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
(Date:9/24/2015)... 2015 Publiceringsförbud fram ... Kerv ( ), det ... världens första kontaktlösa betalningsring på i ... GBP för massproduktion via crowdfunding.  ... Kerv-bärare kan göra direkta kontaktlösa ...
Breaking Biology News(10 mins):
... Mass., May 5 Aware, Inc. (Nasdaq: AWRE ... today reported financial results for its first quarter ended March ... were $4.6 million, a decrease of 22% compared to $5.9 ... its net income and basic and diluted net income per ...
... influenza infection severity have been identified from past outbreaks. ... described in the open access journal BMC Microbiology ... Jonathan Allen and Tom Slezak from Lawrence Livermore National ... acid markers from past pandemic flu strains two weeks ...
... Ind. - Researchers at Purdue University have found a ... in searches for specific genes that shed light on ... Andrew DeWoody, a professor of genetics, and postdoctoral ... step called normalization is no longer necessary with recent ...
Cached Biology News:
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
... Kit is one of the most ... of RNA in solution. The ... than absorbance measurements. As little as ... fluorescence microplate readers and fluorometers using ...
... serum is extensively scrutinized, including ... All horses are of ... worming are controlled and documented ... consistency. Pricing: $12/unit ...
Biology Products: